VivoSeq
Hematology

Myelodysplastic Syndrome

332

Pipeline Programs↗

62

Active Trials↗

116

Companies Involved↗

Myelodysplastic Syndrome is a highly competitive landscape with 332 programs across 116 companies. The most active players are Celyad Oncology SA, Vion Pharmaceuticals, Aileron Therapeutics, Inc.. 17 therapies are approved with 42 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

88/100

Pipeline Velocity

25/100

Mech. Concentration

5/100

Completion Rate

72/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Celyad Oncology SA

3 programs

Phase 1V

Vion Pharmaceuticals

2 programs

Phase 1A

Aileron Therapeutics, Inc.

2 programs

Phase 1S

SymBio Pharmaceuticals

1 program

Phase 1S

Silence Therapeutics plc

1 program

Phase 1C

Cleave Therapeutics, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical7

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Luspatercept

Bristol-Myers Squibb

Filgrastim

Eastern Cooperative Oncology Group

PARP Inhibitor

Hellenic Cooperative Oncology Group

Phase 198

Curcumin

Merck & Co.

Entinostat

Syndax Pharmaceuticals

Sonrotoclax

BeOne Medicines

Pacritinib

OrsoBio, Inc

Belinostat

Acrotech Biopharma Inc.

Phase 2168

Ivosidenib

Servier

Tipifarnib

Kura Oncology, Inc.

Daclizumab

Roche

Etanercept

Immunex

Daunorubicin

Hikma Pharmaceuticals LLC

Phase 342

Gemtuzumab Ozogamicin

Wyeth-Lederle Vaccines

Fludarabine

Sanofi

Clofarabine

Genzyme, a Sanofi Company

Darbepoetin Alfa

Amgen

Mitoxantrone Hydrochloride

Pfizer

Approved17

Calcitriol

Alnylam Pharmaceuticals

Amifostine

Legacy Health System

Deferasirox

Novartis

Azathioprine

Legacy Health System

Decitabine

Sun Pharma

Analysis

Modality Breakdown

84%

Small molecule

289 of 344 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody247%Protein / enzyme144%Cell therapy72%Vaccine72%Antibody–drug conjugate1<1%Peptide1<1%Other1<1%

Small molecule leads; the ring shows all 344 classified programs, each share of the total. Modality classified for 100% of 365 pipeline programs.

Analysis

Trial Status

436

clinical trials

Completed242 · 56%
Terminated72 · 17%
Unknown status39 · 9%
Recruiting35 · 8%
Active, not recruiting22 · 5%
Withdrawn14 · 3%
Other12 · 3%

Clinical Trials

Trial Activity

436 trials

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT06073860·104 enrolled
Ascorbate in Myelodysplastic Syndrome
Recruiting·—·Phase 2·NCT07283900·38 enrolled
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Recruiting·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 3·NCT06641414·490 enrolled
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Recruiting·UUniversity of Southern California·Phase 2·NCT06063486·30 enrolled
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
Recruiting·—·Phase 1·NCT03969446·54 enrolled
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06616636·24 enrolled
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
Recruiting·—·Phase 1·NCT04999943·40 enrolled
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00801489·270 enrolled
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT06419634·105 enrolled
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruiting·EEdgewood Oncology Inc.·Phase 1·NCT04243785·80 enrolled
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Recruiting·GSK logoGSK·Phase 2·NCT06847867·80 enrolled
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03630991·58 enrolled
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Recruiting·SSyntrix Biosystems, Inc.·Phase 1·NCT04245397·151 enrolled
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03383575·63 enrolled
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Recruiting·EEric Stephen Winer, MD·Phase 1·NCT05703542·24 enrolled
Page 1 of 30

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)